Trump's Chinese Import Tariff Hike Could Take Toll On Consumer Health Sector
Executive Summary
Low margins, limited supplier alternatives leave little room for OTC drug marketers in the US to maneuver as ingredients continue to be subject to Chinese import tariffs.
You may also be interested in...
Proposed Tariffs Threaten Ingredient Supply Chain For US Supplement Firms
NPA sounds alarm on Trump administration tariffs on $200bn in Chinese goods scheduled for October. In letter US Trade Representative, NPA President and CEO Daniel Fabricant asks the agency to exempt 57 items from the Harmonized Tariff Schedule that would impact hundreds of dietary ingredients.
Industry Urged To Watch And Wait For US/China Tariff War To Blow Over
Don’t do anything rash to avoid US tariffs on drug products, ingredients and supplies from China, consultants advise. It would be better to just wait to see if the tariff war blows over.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”